Bearish
$ALRN no longer recruiting into Ph 1/2 trial as of mid Jan. That was the IND that covered Ph 1, PTCL Ph 2 and Pfizer/palbo combo. we know ptcl discontinued. Either a big announcement on the horizon,or most likely, Palbo not working and will be officially killed off in June with final report. That leaves myelosuppression in lung cancer. No good idea why myelo trial is only being conducted in the Baltics when all other prior trials at US Centers of Excellence? Does the FDA even accept Bosnian trial data?
  • 1
  • 8